GlassScriptPhysician profile
Catherine D Quinn
NPI 1427403641
$5,899.86
in general payments reported to CMS, 2019-2025
44 companies · $2,708 in 2025
The $2,708 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.54 · 2020: $220 · 2021: $110 · 2022: $799 · 2023: $376 · 2024: $1,615 · 2025: $2,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,382 · Long Term Medical Supply Or Device Loan: $1,196 · Education: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,381.89 |
| Long Term Medical Supply Or Device Loan | $1,196.40 |
| Education | $120.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,471.82 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $610.24 | 2020-2025 | Enhertu, Imfinzi, Calquence |
| Genzyme Corporation | $337.60 | 2019-2025 | |
| Pfizer INC. | $288.72 | 2024-2025 | |
| Incyte Corporation | $248.97 | 2022-2025 | Jakafi, Monjuvi |
| Daiichi Sankyo INC. | $231.47 | 2024-2025 | Enhertu, Datroway |
| Alexion Pharmaceuticals, INC. | $219.15 | 2022-2025 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $215.64 | 2019-2025 | Opdualag |
| Janssen Biotech, INC. | $157.63 | 2022-2025 | Erleada, Darzalex, Tecvayli |
| Rigel Pharmaceuticals, INC. | $150.64 | 2022-2025 | Tavalisse, Gavreto, Rezlidhia |
| Regeneron Pharmaceuticals, INC. | $149.00 | 2025 | Libtayo |
| Mirati Therapeutics, INC. | $144.34 | 2023-2024 | Krazati |
| Merck Sharp & Dohme LLC | $130.83 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Array Biopharma INC | $125.65 | 2024-2025 | Braftovi, Mektovi, Xalkori |
| Astellas Pharma US INC | $122.54 | 2022-2025 | Vyloy |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aveo Pharmaceuticals, INC. | $109.99 | 2021 | |
| Seagen INC. | $95.00 | 2020 | |
| Eisai INC. | $85.21 | 2024-2025 | |
| Celgene Corporation | $84.32 | 2022-2025 | Reblozyl |
| Beigene USA, INC. | $83.04 | 2024-2025 | Brukinsa |
| Springworks Therapeutics, INC. | $81.95 | 2024 | Ogsiveo |
| Abbvie INC. | $78.93 | 2025 | |
| Sobi, INC | $63.31 | 2024 | |
| Deciphera Pharmaceuticals INC. | $60.40 | 2024-2025 | Qinlock, Romvimza |
| Takeda Pharmaceuticals U.S.A., INC. | $58.89 | 2024-2025 | Ninlaro, Alunbrig |
| Ipsen Biopharmaceuticals, INC | $52.59 | 2025 | Onivyde |
| Kite Pharma, INC. | $51.27 | 2024-2025 | Yescarta |
| Glaxosmithkline, LLC. | $42.22 | 2024-2025 | Zejula, Jemperli, Blenrep |
| Bayer Healthcare Pharmaceuticals INC. | $34.88 | 2025 | |
| Stemline Therapeutics INC. | $30.77 | 2025 | Orserdu |
| Genentech USA, INC. | $30.76 | 2025 | Phesgo |
| Jazz Pharmaceuticals INC. | $30.02 | 2025 | |
| Blueprint Medicines Corporation | $26.36 | 2025 | Ayvakit |
| Servier Pharmaceuticals LLC | $24.99 | 2024 | |
| Coherus Oncology, INC. | $23.59 | 2024 | |
| Caris Mpi, INC. | $23.31 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $23.00 | 2024 | |
| Agios Pharmaceuticals, INC. | $22.46 | 2025 | Pyrukynd |
| Telix Pharmaceuticals | $21.35 | 2025 | Illuccix |
| Tempus Ai, INC | $20.74 | 2024 | |
| Amgen INC. | $19.84 | 2022 | |
| Lilly USA, LLC | $16.43 | 2025 | Jaypirca, Verzenio |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Quinn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.